Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma

👉J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

👉Calais G1, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Abstract


  • The Calais et al group designed a randomized clinical trial to test whether the addition of three cycles of chemotherapy during standard radiation therapy would improve disease-free survival in patients with stages III and IV (i.e., advanced oropharynx carcinoma).


  • A total of 226 patients have been entered in a phase III multicenter, randomized trial comparing radiotherapy alone (arm A) with radiotherapy with concomitant chemotherapy (arm B).
  • Radiotherapy was identical in the two arms, delivering, with conventional fractionation, 70 Gy in 35 fractions.
  • In arm B, patients received during the period of radiotherapy three cycles of a 4-day regimen containing carboplatin (70 mg/m(2) per day) and 5-fluorouracil (600 mg/m(2) per day) by continuous infusion.
  • The two arms were equally balanced with regard to age, gender, stage, performance status, histology, and primary tumor site.


  • Radiotherapy compliance was similar in the two arms with respect to total dose, treatment duration, and treatment interruption.
  • The rate of grades 3 and 4 mucositis was statistically significantly higher in arm B (71%; 95% confidence interval [CI] = 54%-85%) than in arm A (39%; 95% CI = 29%-56%).
  • Skin toxicity was not different between the two arms.
  • Hematologic toxicity was higher in arm B as measured by neutrophil count and hemoglobin level.
  • Three-year overall actuarial survival and disease-free survival rates were, respectively,:
    • 51% (95% CI = 39%-68%) versus 31% (95% CI = 18%-49%) and 42% (95% CI = 30%-57%) versus 20% (95% CI = 10%-33%):
      • For patients treated with combined modality versus radiation therapy alone (P =.02 and.04, respectively).
  • The locoregional control rate:
    • Was improved in arm B (66%; 95% CI = 51%-78%) versus arm A (42%; 95% CI = 31%-56%).


  • The statistically significant improvement in overall survival that was obtained supports the use of concomitant chemotherapy as an adjunct to radiotherapy in the management of carcinoma of the oropharynx.

#Arrangoiz #HeadandNeckSurgeon #CancerSurgeon #SurgicalOncologist #OralCavityCancer #PhryngealCancer #Teacher #Surgeon

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s